Ernexa Therapeutics (ERNA) Competitors $1.55 -0.06 (-3.73%) Closing price 03:59 PM EasternExtended Trading$1.64 +0.09 (+5.81%) As of 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERNA vs. ATHE, ATNM, TELO, ADVM, LTRN, PRLD, ALGS, BRNS, NBRV, and SLGLShould you be buying Ernexa Therapeutics stock or one of its competitors? The main competitors of Ernexa Therapeutics include Alterity Therapeutics (ATHE), Actinium Pharmaceuticals (ATNM), Telomir Pharmaceuticals (TELO), Adverum Biotechnologies (ADVM), Lantern Pharma (LTRN), Prelude Therapeutics (PRLD), Aligos Therapeutics (ALGS), Barinthus Biotherapeutics (BRNS), Nabriva Therapeutics (NBRV), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical products" industry. Ernexa Therapeutics vs. Its Competitors Alterity Therapeutics Actinium Pharmaceuticals Telomir Pharmaceuticals Adverum Biotechnologies Lantern Pharma Prelude Therapeutics Aligos Therapeutics Barinthus Biotherapeutics Nabriva Therapeutics Sol-Gel Technologies Alterity Therapeutics (NASDAQ:ATHE) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability. Is ATHE or ERNA more profitable? Alterity Therapeutics has a net margin of 0.00% compared to Ernexa Therapeutics' net margin of -7,652.75%. Company Net Margins Return on Equity Return on Assets Alterity TherapeuticsN/A N/A N/A Ernexa Therapeutics -7,652.75%N/A -682.08% Do analysts rate ATHE or ERNA? Alterity Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 142.42%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Alterity Therapeutics is more favorable than Ernexa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Ernexa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer ATHE or ERNA? In the previous week, Ernexa Therapeutics had 3 more articles in the media than Alterity Therapeutics. MarketBeat recorded 3 mentions for Ernexa Therapeutics and 0 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 0.00 beat Ernexa Therapeutics' score of -0.20 indicating that Alterity Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Alterity Therapeutics Neutral Ernexa Therapeutics Neutral Do insiders & institutionals believe in ATHE or ERNA? 2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by company insiders. Comparatively, 4.5% of Ernexa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, ATHE or ERNA? Alterity Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Ernexa Therapeutics has a beta of 5.42, meaning that its share price is 442% more volatile than the S&P 500. Which has higher valuation & earnings, ATHE or ERNA? Alterity Therapeutics has higher earnings, but lower revenue than Ernexa Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlterity TherapeuticsN/AN/A-$12.54MN/AN/AErnexa Therapeutics$580K20.50-$44.54M-$8.31-0.19 SummaryAlterity Therapeutics beats Ernexa Therapeutics on 8 of the 12 factors compared between the two stocks. Get Ernexa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERNA vs. The Competition Export to ExcelMetricErnexa TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.89M$2.78B$5.76B$9.65BDividend YieldN/A1.76%3.91%4.09%P/E Ratio-0.1921.6630.7825.12Price / Sales20.50715.76456.64116.46Price / CashN/A25.4525.2228.45Price / Book3.105.439.375.95Net Income-$44.54M$31.83M$3.26B$265.46M7 Day Performance-8.28%1.03%1.88%0.96%1 Month Performance-21.72%2.29%3.73%2.47%1 Year Performance-94.10%9.79%28.93%20.24% Ernexa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERNAErnexa Therapeutics0.6039 of 5 stars$1.55-3.7%N/A-93.8%$11.89M$580K-0.1910Earnings ReportShort Interest ↑ATHEAlterity Therapeutics2.972 of 5 stars$5.30-0.4%$12.00+126.4%+275.5%$47.17MN/A0.0010Positive NewsATNMActinium Pharmaceuticals2.9296 of 5 stars$1.51+2.7%$4.50+198.0%-6.0%$47.11MN/A-1.0930Positive NewsShort Interest ↓TELOTelomir Pharmaceuticals2.4606 of 5 stars$1.55-1.9%$15.00+867.7%-62.7%$47.03MN/A0.001Earnings ReportGap DownADVMAdverum Biotechnologies4.1078 of 5 stars$2.47+10.3%$23.80+863.6%-57.0%$46.79M$1M0.00190News CoverageEarnings ReportAnalyst RevisionLTRNLantern Pharma2.9304 of 5 stars$4.45+2.8%$25.00+461.8%+5.0%$46.70MN/A0.0020Earnings ReportPRLDPrelude Therapeutics3.0254 of 5 stars$0.84+1.3%$4.50+437.0%-81.9%$46.69M$7M0.00120News CoverageEarnings ReportAnalyst ForecastALGSAligos Therapeutics4.2634 of 5 stars$7.43-1.8%$70.00+842.1%+1,570.2%$46.28M$3.94M0.0090News CoverageAnalyst ForecastBRNSBarinthus Biotherapeutics2.6058 of 5 stars$1.22+7.0%$6.25+412.3%-4.8%$45.99M$14.97M0.00107News CoverageNegative NewsShort Interest ↑NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070SLGLSol-Gel Technologies0.9804 of 5 stars$15.25-5.9%$40.00+162.3%+273.7%$45.14M$11.54M0.0050Positive NewsEarnings ReportGap Up Related Companies and Tools Related Companies ATHE Alternatives ATNM Alternatives TELO Alternatives ADVM Alternatives LTRN Alternatives PRLD Alternatives ALGS Alternatives BRNS Alternatives NBRV Alternatives SLGL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERNA) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ernexa Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ernexa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access